Alan Colowick

Alan B. Colowick is the founder of Inventages II.
Current jobs include Director at Xylocor Therapeutics, Inc. since 2018, Director at ReCode Therapeutics, Inc. since 2022, Independent Director at Alumis, Inc. since 2022, Director at InCarda Therapeutics, Inc. since 2018, Director at Solve Therapeutics, Inc. since 2021, Director at Anumana, Inc. since 2022, and Director at Teon Therapeutics, Inc. since 2017.
Former jobs include Chief Executive Officer at Gloucester Pharmaceuticals, Inc. from 2008 to 2010, Chairman at Principia Biopharma, Inc. from 2017 to 2020, Chairman at VelosBio, Inc. from 2018 to 2020, Independent Director at Achaogen, Inc. from 2015 to 2017, Director at Naryx Pharma, Inc., Independent Director at Personalis, Inc. from 2019 to 2023, Director at Nora Therapeutics, Inc., Independent Non-Employee Class I Director at Dimension Therapeutics, Inc. from 2015 to 2017, Director at Human Longevity, Inc. from 2016 to 2019, Independent Director at Harpoon Therapeutics, Inc. from 2021 to 2023, Independent Director at Maze Therapeutics, Inc. from 2024 to 2025, Independent Director at ACELYRIN, Inc. from 2021 to 2025, Independent Non-Executive Director at AC Immune SA from 2021 to 2023, Vice President-European Medical Affairs at Amgen, Inc. from 1999 to 2005, Executive Vice President at Celgene Corp.
from 2010 to 2017, President-Oncology Division at Geron Corp.
from 2006 to 2008, Chief Medical Officer at Threshold Pharmaceuticals, Inc. from 2005 to 2006, MD-Europe, Middle East & Africa Region at Celgene International SARL, Executive Partner & Private Equity at Sofinnova Investments, Inc. from 2017 to 2021, and Principal at Harvard University in 1999.
Education includes undergraduate degree from The University of Colorado, graduate degree from Harvard T.H.
Chan School of Public Health, and doctorate from Stanford University School of Medicine.